JAAQ Secures €15M Series B to Accelerate Digital Health Partnerships Across Europe

JAAQ, the London-based digital health platform that connects healthcare providers with clinical and business experts, has closed a €15 million Series B funding round. The capital injection marks a significant milestone for the startup and signals growing investor confidence in B2B digital health infrastructure across the UK and Europe.

The round was led by leading European healthcare investors, positioning JAAQ to expand its partnership network, enhance its platform capabilities, and establish deeper roots in key NHS trusts and European health systems. For UK founders scaling healthcare solutions, the JAAQ case offers practical lessons in navigating regulated markets, building trust with institutional partners, and structuring growth-stage funding rounds.

What JAAQ Does: The Digital Health Infrastructure Play

JAAQ operates in the B2B digital health space—specifically, it has built a marketplace connecting healthcare organisations with vetted consultants, subject matter experts, and clinical advisors. Rather than replacing clinicians or offering direct patient care, JAAQ acts as infrastructure: it helps hospital trusts, health systems, and medical device manufacturers access expert networks, accelerate innovation projects, and de-risk strategic partnerships.

The platform is particularly relevant in the UK context, where NHS trusts operate under budget constraints and need efficient ways to tap specialist knowledge without lengthy procurement cycles. JAAQ's model reduces friction by pre-vetting providers, standardising engagement workflows, and handling compliance legwork—tasks that would otherwise slow institutional decision-making.

Founded in 2018, JAAQ has spent the past five years establishing credibility with major healthcare institutions. This trust-building phase is critical in healthcare: unlike consumer apps that scale through viral adoption, B2B health platforms succeed by embedding themselves into the operational workflows of large, regulated organisations. The €15M Series B validates that JAAQ has crossed that threshold.

The Funding Round: Capital Structure and Strategic Implications

A €15 million Series B is a substantial but measured round for a digital health infrastructure play. For context, UK healthcare startups raising at this stage typically secure £10–20 million, depending on traction, geography, and market focus. JAAQ's euro-denominated raise reflects its pan-European ambitions—rather than purely UK-focused growth, the startup is positioned to scale across multiple health systems.

Why This Round Matters for the UK Startup Ecosystem

JAAQ's funding round demonstrates several important dynamics in the UK digital health funding landscape:

• B2B infrastructure plays remain fundable. While consumer health apps and AI diagnostics tools attract headlines, institutional B2B solutions—those solving workflow, access, and compliance problems—continue to attract serious capital. This is a less crowded segment.
• European investor appetite for UK health tech persists. Despite post-Brexit uncertainty, European VCs recognise that UK health tech founders have unique advantages: access to NHS data, regulatory familiarity, and a global English-speaking talent pool.
• Regulatory compliance is a moat. JAAQ's ability to navigate GDPR, NHS data governance, and varying health system regulations across Europe has likely been a key differentiator. Investors increasingly value regulatory expertise as a defensible advantage.
• Exit pathways remain viable. UK digital health companies can be attractive acquisition targets for larger healthcare platforms, IT vendors, and health systems looking to build internal capability. JAAQ's institutional customer base positions it well for such outcomes.

What the Round Likely Funds

Series B capital in digital health typically flows into three areas: product development, go-to-market expansion, and operational infrastructure. For JAAQ, this probably means:

• Expanding the expert network across new specialties and geographies.
• Building deeper integrations with NHS trusts and European health systems—including API connections to hospital IT systems and electronic health records (EHRs).
• Hiring in regulatory affairs, clinical operations, and sales—roles that are expensive but essential when selling into healthcare institutions.
• Establishing local presence in key European markets, likely through hiring or partnership agreements.

UK founders should note that institutional healthcare sales are slow and expensive. A €15M Series B for JAAQ likely means 18–24 months of runway before the company needs to demonstrate significant revenue growth or approach a Series C. This reflects the reality of NHS and health system sales cycles, which routinely span 12–18 months from initial conversation to contract signature.

Lessons for UK Health Tech Founders: Building Trust in Regulated Markets

JAAQ's success offers several actionable insights for UK entrepreneurs building B2B health solutions:

Invest Early in Regulatory and Compliance Infrastructure

Healthcare is regulated for good reason—patient safety, data privacy, and audit trails are non-negotiable. JAAQ's ability to operate across multiple jurisdictions suggests the team has invested heavily in compliance architecture from the start. Specifically:

• GDPR compliance is table stakes in Europe. Ensure your data architecture, consent flows, and retention policies are auditable and transparent.
• If you're working with NHS data, you need to understand NHS Data Security and Protection Toolkit (DSPT) requirements. The DSPT is now mandated for NHS contractors, and compliance can take months to achieve.
• Consider hiring a Compliance or Regulatory Affairs lead early, even if it seems premature. The cost is far less than remediating compliance issues post-launch or losing customer trust due to a breach.
• Document everything. Healthcare institutions and regulators want to see clear evidence of your security practices, incident response procedures, and quality assurance processes.

Build Direct Relationships with NHS Trusts Early

JAAQ's customer base likely includes dozens of NHS trusts—a slow process to build but an enormous moat once established. UK health tech founders should:

• Target specific NHS trusts with innovation teams or digital transformation priorities. Many trusts now have Chief Digital Officers or innovation leads who are mandate to explore new solutions.
• Start with pilots. NHS trusts are reluctant to commit large budgets to unproven solutions. Offer a limited pilot—3–6 months with a specific team or department—to demonstrate value before asking for institution-wide rollout.
• Leverage NHS procurement routes. Understand whether your solution qualifies for frameworks like the NHS Digital Technology Assessment Criteria (DTAC), which can streamline purchasing decisions.
• Join relevant networks. Bodies like the NHS Innovation Accelerator and regional innovation hubs can introduce you to decision-makers and reduce sales friction.

Plan for Slow Cash Flow

Institutional sales in healthcare typically come with long payment terms—60–90 days is common, and some NHS trusts operate on even longer cycles. JAAQ's Series B funding cushions this cash flow reality. UK founders should:

• Raise more than you think you need. Healthcare B2B sales involve longer sales cycles and longer payment terms than SaaS in other sectors.
• Build cash management into your financial planning. Don't assume revenue will arrive when contracts are signed.
• Consider alternative revenue models—such as per-consultation or usage-based pricing—that align revenue timing with actual customer value realisation.

The UK Healthcare Funding Landscape in 2024

JAAQ's raise reflects a broader shift in UK health tech funding. While early-stage digital health startups continue to struggle with seed funding scarcity, Series B and beyond rounds for proven business models remain active.

Where UK Health Tech Founders Can Access Capital

Beyond traditional VCs, UK health tech founders have access to several funding pathways:

• SEIS and EIS tax relief. If you're an early-stage health tech company, SEIS (Seed Enterprise Investment Scheme) offers 50% income tax relief for investors, making your round more attractive to angel investors and small family offices. HMRC provides guidance on advance assurance, which can accelerate fundraising by confirming tax relief eligibility upfront.
• Innovate UK grants. The UK Innovation Agency runs competitive grant programmes for companies developing innovative health tech solutions. These grants don't require equity dilution and can provide £100k–£2M depending on the programme. Check Innovate UK's website for current deadlines.
• Start Up Loans. For early-stage founders building in the health sector, Start Up Loans offers government-backed loans up to £25k at competitive rates, helping you preserve equity in seed rounds.
• Strategic corporate investment. Large healthcare providers, pharmaceutical companies, and health tech platforms increasingly make corporate venture investments in smaller innovators. This route can be faster than traditional VC but requires navigating corporate decision-making and potential conflicts of interest.

For founders at the Series B stage like JAAQ, the options expand significantly. European funds focused on climate tech, deep tech, and health tech are actively deploying capital into the UK and across Europe. The key is demonstrating traction with institutional customers and a clear path to profitability or a viable exit.

The Regulatory Advantage

One underappreciated advantage of building health tech in the UK: regulatory familiarity and relationships. The UK Health Security Agency, the Care Quality Commission (CQC), and NHS leadership are all accessible to founders. Building relationships with these bodies—either formally through regulatory consultations or informally through industry networks—can accelerate credibility and funding prospects.

JAAQ's ability to operate across UK and European health systems suggests the team has invested in understanding regulatory nuances across jurisdictions. This expertise is valuable and scarce, which likely strengthened their funding pitch.

Scaling Digital Health: Lessons for Growth-Stage Founders

As JAAQ moves from Series B to scaling, several operational challenges emerge. UK health tech founders should watch how JAAQ navigates these:

Internationalisation Without Losing Focus

Growing from UK to pan-European operations requires more than translation. Each health system operates differently: procurement rules vary, reimbursement models differ, and trust-building timelines shift. JAAQ's euro-denominated raise suggests intentional internationalisation, likely through:

• Hiring local sales and operations teams in key markets.
• Adapting product features and compliance approaches to local regulations.
• Building partnerships with local health system integrators and consultancies.
• Maintaining core product and data infrastructure while allowing flexibility in go-to-market approach.

This balancing act is difficult and expensive. Founders should be realistic: scaling to multiple countries requires capital and patience. JAAQ's €15M likely reflects investor confidence that the team can execute this expansion without losing operational control or product quality.

Building Talent for Regulated Markets

Health tech attracts idealistic talent—many engineers and product managers want to work on problems that matter. However, regulated industries also require specialists: compliance officers, clinical advisors, regulatory affairs managers, and healthcare-experienced sales professionals.

These roles are expensive and competitive. JAAQ's Series B funding likely includes significant headcount expansion, particularly in back-office and compliance roles that don't generate visible user value but are essential for operating in healthcare.

Network Effects and Platform Dynamics

JAAQ's business model depends on network effects: the value of the platform increases as more experts join and more healthcare organisations use it. This creates a chicken-and-egg problem early on but becomes a powerful moat once the network reaches critical mass.

Series B capital often funds the effort to reach that critical mass in a market. For JAAQ, this likely means subsidising expert sign-ups, investing in platform features that make matching more efficient, and doubling down on customer success to ensure healthcare organisations get value and recommend JAAQ to peers.

What's Next for JAAQ and UK Health Tech

With €15M in the bank, JAAQ is likely targeting a Series C round within 18–24 months, assuming continued customer growth and revenue traction. The path to Series C typically requires:

• Revenue acceleration. Moving from pilot mode to significant customer contracts, with demonstrable ROI for healthcare partners.
• Unit economics clarity. Showing that customer acquisition cost and lifetime value are aligned for profitable scaling.
• Competitive moat. Demonstrating unique advantages—whether network effects, regulatory expertise, or customer switching costs—that protect the business from competition.
• Market expansion traction. Early wins in one or two new European markets, demonstrating the model's geographic scalability.

For the UK health tech ecosystem broadly, JAAQ's raise is a positive signal. It shows that well-executed B2B health solutions targeting institutional buyers remain fundable and valuable. While the media often focuses on consumer health apps or AI diagnostics startups, the unglamorous work of improving healthcare operations and decision-making is where real business value often lies.

Actionable Takeaways for UK Health Tech Founders

If you're building a health tech solution in the UK, JAAQ's success offers several concrete lessons:

• Build for institutions first. NHS trusts and health systems are slow to adopt but loyal once convinced. Invest in understanding their needs, workflows, and constraints.
• Prioritise compliance from day one. Don't treat regulatory requirements as an afterthought. Compliance is a competitive advantage in healthcare.
• Plan for long sales cycles and longer payment terms. Raise capital accordingly. A Series B that feels large for a B2B SaaS company may be right-sized for healthcare B2B.
• Leverage UK regulatory relationships. Your proximity to NHS leadership and UK regulators is an advantage over foreign competitors. Use it.
• Consider tax-efficient funding routes. SEIS, EIS, and Innovate UK grants can preserve equity in early rounds, giving you more runway to reach Series A traction.
• Build for European scale, not just UK. The largest healthcare markets in Europe offer more customer diversity and reduce dependence on NHS adoption. Plan for geographic expansion early.
• Invest in customer success, not just sales. Healthcare customers need support to realise value. Those that do become references for future deals.

JAAQ's €15M Series B is a milestone not just for the company but for the UK health tech ecosystem. It demonstrates that founders willing to do the hard work of understanding regulated markets, building trust with large institutions, and iterating on product-market fit can attract significant capital and build valuable, durable businesses.

For UK entrepreneurs in the health sector, the path forward is clear: focus on solving real problems for healthcare organisations, invest in compliance and trust, and think pan-European from the start. Capital will follow.